Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avdoralimab - Innate Pharma

Next Previous
Drug Profile

Avdoralimab - Innate Pharma

Alternative Names: Anti-C5aR-215; IPH-5401; NN-8210; NNC-0215-0384

Latest Information Update: 23 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Developer AstraZeneca; Innate Pharma; Novo Nordisk
  • Class Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Complement C5a receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Bullous pemphigoid; Chronic urticaria; COVID-19 pneumonia; Liver cancer; Non-small cell lung cancer; Rheumatoid arthritis; Solid tumours

Most Recent Events

  • 31 Mar 2024 Centre Hospitalier Universitaire de Nice completes a phase II trial in Bullous pemphigoid (In adults, In the elderly) in France (SC) (NCT04563923) (EudraCT2020-002912-34)
  • 23 Mar 2023 Avdoralimab - Innate Pharma is available for licensing as of 23 Mar 2023
  • 23 Mar 2023 Discontinued - Phase-II for Bullous pemphigoid (In the elderly, In adults) in France (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top